Dr Reddy terminates Armis Biopharma's investigation license of DFA-02

Hyderabad: Dr. Reddy’s Laboratories Ltd. has announced the termination of the license granted to Armis Biopharma, Inc. (formerly known as CHD Bioscience, Inc.) for its investigational antibacterial product, DFA-02, for the prophylaxis of surgical site infections (SSIs).

As a result of the termination, Dr. Reddy's has regained worldwide rights to DFA-02 and is currently evaluating its options to take the program forward.

DFA-02 is a combination, broad-spectrum antibacterial in situ gel which is being investigated for the prophylaxis of SSIs as an adjunct to conventional preoperative antibiotic prophylaxis. DFA-02 has been studied in several phases 1 and 2 clinical studies and has demonstrated clinical efficacy in several key segments of patients who were at high risk for SSIs.